Creation of Side-to-Side Compression Anastomosis Using the GT Metabolic MagDI System in Canada to Achieve Duodeno-Ileal Diversion in Adults With Obesity and With or Without Type 2 Diabetes Mellitus (MagDI Canada Study)

Status: Recruiting
Location: See all (3) locations...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The objective of the MagDI Canada study is to evaluate the performance and safety of the MagDI System in eligible participants who are indicated for a duodeno-ileal (small bowel) side-to-side anastomosis procedure for partial intestinal diversion as one example of a small bowel clinical procedure requiring a side-to-side anastomosis. The secondary objective includes initial efficacy of the duodeno-ileal diversion using the MagDI System.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: f
View:

• Between 18-65 years of age, at the time of informed consent.

• Body Mass Index (BMI) between 30-50 kg/m2

• Meets one of the following criteria:

‣ Type 2 Diabetes Mellitus (T2DM; defined as HbA1c ≥ 6.5%) or weight regain following previous sleeve gastrectomy (≥ 12 months); OR

⁃ Type 2 Diabetes Mellitus (T2DM; defined as HbA1c ≥ 6.5%) or weight regain following previous endoscopic sleeve gastroplasty (≥ 12 months); OR

⁃ Type 2 Diabetes Mellitus (defined as HbA1c ≥ 6.5%) with a Body Mass Index between 30-35 and without previous sleeve gastrectomy and no plan to perform a concurrent sleeve gastrectomy.

• Participant agrees to refrain from any type of additional bariatric or reconstructive surgery that would affect body weight for the duration of the study.

• Participant has been informed of the nature of the study and agrees to its provisions, complying with study required testing, medications, follow-up visits, and has provided written informed consent.

Locations
Other Locations
Canada
McGill University
NOT_YET_RECRUITING
Montreal
University of Toronto
NOT_YET_RECRUITING
Toronto
Westmount Square Surgical Center
RECRUITING
Westmount
Contact Information
Primary
Lisa Griffin Vincent, PhD
clinical@gtmetabolic.com
+1 763-200-1416
Backup
Josh Schumacher
clinical@gtmetabolic.com
+1 763-200-1416
Time Frame
Start Date: 2024-05-10
Estimated Completion Date: 2027-02
Participants
Target number of participants: 60
Treatments
Experimental: Magnet System, DI Biofragmentable
GT Metabolic Solutions Magnet System, DI Biofragmentable (MagDI System)
Related Therapeutic Areas
Sponsors
Leads: GT Metabolic Solutions, Inc.

This content was sourced from clinicaltrials.gov

Similar Clinical Trials